Featured Image
Why is it important?
The temporal correlation between teprotumumab initiation and RCVS's symptom onset raises concern for the potential involvement of teprotumumab in triggering RCVS via disrupting cerebrovascular modulation. Further research is needed to investigate this proposed association.
Perspectives
RCVS is a potential adverse effect of teprotumumab, and further research is needed to confirm this association. If a causal association is confirmed, it is necessary to investigate if there are risk factors that might increase the risk of RCVS development in certain patients receiving teprotumumab rather than the others. Moreover, close monitoring will be needed for patients receiving teprotumumab for GED.
Dr. Mohamed Elfil
University of Nebraska Medical Center
Read the Original
This page is a summary of: Reversible cerebral vasoconstriction syndrome due to teprotumumab: two case reports, Oxford Medical Case Reports, August 2024, Oxford University Press (OUP),
DOI: 10.1093/omcr/omae085.
You can read the full text:
Contributors
The following have contributed to this page
